Monomethyl auristatin E

Monomethyl auristatin E

• CAS Number: 474645-27-7
• UNSPSC Description: Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
• Target Antigen: ADC Cytotoxin; Apoptosis; Microtubule/Tubulin
• Type: ADC Related
• Related Pathways: Antibody-drug Conjugate/ADC Related;Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Monomethyl-auristatin-E.html
• Solubility: DMSO : ≥ 48 mg/mL|Ethanol : 50 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@@H](CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C2=CC=CC=C2)O)=O)=O)OC)C)=O)C(C)C)=O
• Molecular Weight: 717.98
• References & Citations: [1]Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.|[2]Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.
• Shipping Conditions: Blue Ice
• Clinical Information: Phase 4